Invex Therapeutics Ltd. (AU:IXC) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Invex Therapeutics Ltd has announced the results of its Annual General Meeting, where several resolutions, including the adoption of the remuneration report and the election of directors, were carried, while the issuance of securities under an incentive plan was not approved. The company continues its focus on repurposing the drug Exenatide for neurological treatments, underlining its commitment to innovation in biopharmaceuticals.
For further insights into AU:IXC stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue